{
    "2018-11-05": [
        [
            {
                "time": "2018-05-04",
                "original_text": "4 months after drug approval, Achaogen eyes fire sale",
                "features": {
                    "keywords": [
                        "drug approval",
                        "Achaogen",
                        "fire sale"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-11-05",
                "original_text": "Pre-Market Most Active for Nov 5, 2018: AAPL, GE, ACRX, CHK, TEVA, GGB, AMD, QQQ, SQQQ, LYG, NVS, TQQQ",
                "features": {
                    "keywords": [
                        "Pre-Market",
                        "Most Active",
                        "AAPL",
                        "GE",
                        "ACRX",
                        "TEVA",
                        "AMD"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "technology",
                        "energy",
                        "healthcare",
                        "semiconductors"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-11-05",
                "original_text": "Novartis Issues R&D Update; Plans 60 Major Submissions From 2019 To 2021",
                "features": {
                    "keywords": [
                        "Novartis",
                        "R&D Update",
                        "Major Submissions",
                        "2019 to 2021"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}